NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Holder | Stake |
|---|---|
| Tikri Partners | 1.97% |
| Rajni Tarun Jain | 1.42% |
| Acadian Emerging Markets Micro-cap Equity Master Fund | 1.10% |
| Nisarg Ajaykumar Vakharia | 1.05% |
| Investor Education and Protection Fund Authority Ministry of Corporate Affairs | 1.00% |
| Document | Date |
|---|---|
| Annual report FY2026 VENUS REMEDIES LIMITED - FY 2025-26 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Revenue from operations: ₹76,873.48 lakhs (FY 2026), up 19. | 2026-07-24 |
| Quarterly results · Q1 FY27 VENUS REMEDIES LIMITED - DOCUMENT SUMMARY HEADLINE NUMBERS • Q1 FY2026-27 (Quarter ended June 30, 2026) Standalone Revenue from Operations: INR 178. | 2026-07-20 |
| Quarterly results · Q4 FY26 VENUS REMEDIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • FY 2025-26 Revenue from Operations: ₹768.73 crore (up 19.3% from ₹644.47 crore in FY 2 | 2026-05-26 |
| Quarterly results · Q3 FY26 VENUS REMEDIES LIMITED – FINANCIAL SUMMARY Q3 & 9M FY2025-26 Results (As of 29 January 2026) --- HEADLINE NUMBERS STANDALONE FINANCIAL RESULTS • Q | 2026-01-29 |
| Quarterly results | 2026-01-22 |
| Quarterly results · Q2 FY26 VENUS REMEDIES LIMITED - Q2 FY2025-26 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Quarter ended 30th September 2025 unaudited financial results app | 2025-11-10 |
| Quarterly results · Q1 FY26 VENUS REMEDIES LIMITED – Q1 FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Consolidated Revenue from Operations (Q1 FY2026): ₹131.90 Crores vs ₹108.61 | 2025-08-01 |
| Annual report FY2025 VENUS REMEDIES LIMITED – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from Operations: ₹64,788.60 lakhs (FY 2024-25) vs ₹60,144 | 2025-07-24 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹10 / share ex-date Aug 7, 2026 | 2026-08-07 |
| Announcement | Date |
|---|---|
| Disclosure of information received from promoter group companies regarding merger Venus Remedies Limited has announced that it received information from its promoter group companies regarding a potential merger. This is a disclosure announcement rather than a completed tr | 2026-03-02 |
| Awarded Rs. 11.78 crore incentive under PLI scheme Venus Remedies Limited, a pharmaceutical company, has received government incentive approval worth Rs. 11.76 crore (approximately $1.4 million USD) under India's Production Linked Incentive | 2026-01-22 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Venus Remedies Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.